{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-019117","form_type":"8-K","ticker":"PAVM","cik":"0001624326","company_name":"PAVmed Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.299104+00:00","generated_at":"2026-06-02T00:52:05.325176+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PAVmed reports Q1 2024 net loss of $22.8M; EsoGuard revenue flat QoQ at $1.0M","bullets":["GAAP net loss $22.8M ($2.62 per share); non-GAAP adjusted loss $8.6M ($0.99 per share).","EsoGuard revenue $1.0M (flat vs Q4 2023, +124% YoY); operating expenses $15.0M.","Lucid completed $29.8M Series B Preferred Stock offering to strengthen balance sheet.","Secured July 17, 2024 MolDX pre-submission meeting for technical assessment under LCD.","Veris Health completed MOU with Ohio State's James Cancer Hospital for pilot program."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-019117","json":"https://secwatch.observer/filing/0001493152-24-019117.json","markdown":"https://secwatch.observer/filing/0001493152-24-019117.md","text":"https://secwatch.observer/filing/0001493152-24-019117.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1624326/000149315224019117/0001493152-24-019117-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1624326/000149315224019117/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:52:05.325176+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"abdc847857e271232f310f2c284cfb9ca1560163","claim":"PAVmed Inc. reported three months ended March 31, 2024 results: revenue $1.0 million, net income $22.8 million, EPS $(2.62) per common share.","evidence_excerpt":"well in furtherance of this revised strategy.” Highlights from the first quarter and recent weeks include : ● Yesterday, Lucid reported that 1Q24 EsoGuard ® revenue was $1.0 million, which was flat compared to 4Q23 and represents a 124 percent increase from 1Q23. ● Strengthened balance sheet by Lucid’s completion of a $29.8 million Series B Preferred Stock","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1624326/000149315224019117/0001493152-24-019117-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2024"},{"label":"Revenue","value":"$1.0 million"},{"label":"Net income","value":"$22.8 million"},{"label":"EPS","value":"$(2.62) per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}